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Abstract: Trastuzumab is a monoclonal humanized antibody that has revolutionized the 
treatment of patients with Her2-positive breast cancer. Already well established in advanced 
stage disease, the substance was recently introduced in the adjuvant setting, reducing disease 
recurrences by more than 50% and mortality by approximately one third. Trastuzumab is a 
rationally designed substance which binds to cancer cells expressing the targeted antigen, and, 
by different mechanisms, causes tumor cell degradation. However, only one third of patients 
have an initial response to trastuzumab therapy, and the majority of initial responders dem-
onstrate disease progression within 1 year of treatment initiation. It is therefore necessary to 
gain further insight into mechanisms of resistance, and develop ways to overcome those. In 
this article, the role of trastuzumab in early and advanced stage breast cancer is reviewed. We 
discuss current understandings of the speciﬁ  c tumor biology of Her2-positive breast cancer, 
and review the mechanism of action of trastuzumab. Further, we try to highlight possible 
mechanisms of resistance.
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Background
Breast cancer is one of the most prevalent cancers in the world, and holds responsible 
for almost half a million deaths per year worldwide. While incidence is rising, screening 
and recent advances in adjuvant treatment caused reduction in mortality in early stage 
disease over the last decade (American Cancer Society Facts and Figures 2005; World 
Health Organization Facts and Figures 2007). Yet, even in stage I and II disease, 
approximately one third of patients are expected to experience disease recurrence 
(Faneyte et al 2004). With few exemptions, breast cancer in this situation is incurable, 
and patients will ﬁ  nally succumb to their disease. Today, a prolongation of overall 
survival due to a wide range of treatment options is possible, yet median life expectancy 
after recurrence remains low, between 24 and 30 months (American Cancer Society 
Facts and Figures 2005; World Health Organization Facts and Figures 2007).
Relatively early it was anticipated that major biologic differences exists between 
estrogen receptor- (ER) positive and ER-negative disease. More recently it was discov-
ered that up to 25% of breast cancers have overexpression of Her2, deﬁ  ning a high-risk 
breast cancer subtype (Slamon et al 1987; Paik et al 1990; Kallioniemi et al 1991; Boss 
et al 2003). Progresses in microarray technology allowed the simultaneous evaluation 
of the expression of tens of thousands of genes, thereby increasing our understanding of 
cancer biology, and proving that breast cancer is a heterogeneous disease (Sørlie et al 
2001; Clarke et al 2001; van de Vijver 2002; van’t Veer 2002). At least four different 
subtypes are currently deﬁ  ned: Her2 positive, normal breast-like, basal-like (often 
also referred to as triple negative), and the two luminal subtypes, A and B (possibly 
endocrine responsive and Her2 negative) (Sørlie et al 2001; van de Vijver 2002; van’t 
Veer 2002). Due to these insights, while yet far from perfect, patients are treated with Biologics: Targets & Therapy 2007:1(1) 20
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regimens that are risk adapted, and, wherever possibly, 
tailored to the speciﬁ  c tumor biology of their individual 
disease.
Still, a number of patients are not adequately treated, 
as they will eventually develop metastatic disease. Other 
patients might not have needed adjuvant therapy at all, and 
are therefore considered overtreated. In the future, it is hoped 
for that differences in gene expression proﬁ  ling might lead 
our decision to treat (or not to treat) a certain patient, or might 
even help in choosing the most appropriate substances.
Breast cancer biology: the Her2 subtype
The Her2 subtype of breast cancer can be identiﬁ  ed both 
by histopathologic methods and by gene expression pro-
ﬁ  ling. Overexpression of Her2 in breast cancer cells is 
well known to be associated with high recurrence rate 
and poor outcome (Slamon et al 1987; Paik et al 1990; 
Kallioniemi et al 1991; Boss et al 2003). Her2 (Her2/neu, 
erbB2) is a transmembrane tyrosine kinase molecule of 
the Her family of human growth factor receptors, coded 
by the Her2/neu gene on chromosome p17 (Bargmann et al 
1986; Akiyama et al 1988). The molecule forms homo- or 
heterodimers with other members of this family (EGFR, 
Her3, and Her4). It is of importance that heterodimers 
of EGFR and Her2 have higher stability and therefore 
cause prolonged receptor signaling compared with EGFR 
homodimers, a fact that serves as rationale for dual tar-
geting of EGFR and Her2 (Konecny et al 2006; Xia et al 
2006). Following receptor activation, phosphorylation of 
tyrosine residues on the cytoplasmatic domain activates 
downstream signaling pathways, namely the cell survival 
PI3K (phosphatidylinositol 3-kinase)/Akt pathway, and 
cell proliferation pathways mediated by mitogen-activated 
protein kinase (MAPK). Furthermore, increased signal-
ing via those pathways leads to an increase in vascular 
endothelial growth factor (VEGF) expression (Yen L et al 
2000; Izumi et al 2002), most probably via an increase in 
hypoxia inducible factor (HIF) 1α (Laughner et al 2001). 
This is due to mTor and MAPK signaling, which in turn 
may be blocked by trastuzumab.
It was therefore suggested that the positive association 
between Her2 and VEGF expression implicates VEGF in the 
aggressive phenotype exhibited by Her2 overexpression, and 
this might support the use of combination therapies directed 
against both Her2 and VEGF (Pegram and Reese 2002; 
Konecny et al 2004).
In recent years, existence of a molecular crosstalk 
between the ER and signaling pathways downstream of 
growth factor receptors was reported by different groups. 
MAPK and pAKT may cause a ligandless activation of the 
AF-1 domain of membrane bound and cytoplasmatic ER. As 
this domain is not blocked by tamoxifen, it is widely believed 
that this constitutes the main mechanism of resistance to 
tamoxifen in Her2-positive disease (Schiff et al 2004).
Interestingly, while other receptors of the Her family have 
speciﬁ  c ligands, Her2 appears to represent a ligandless recep-
tor, as no speciﬁ  c Her2 ligand was yet identiﬁ  ed. Charac-
terization of the crystal structure of the extracellular domain 
showed that Her2 has a constitutively open conformation. 
This open conformation is needed for receptor dimerization 
and signal transduction. Indeed, the extracellular domain of 
Her2 is similar to that of ligand bound EGFR (Cho et al 2003). 
As mentioned above, stability of EGFR and Her2 heterodi-
mers is higher compared with EGFR homodimers (Konecny 
et al 2006; Xia et al 2006). Therefore, Her2 is believed to act 
mainly as enhancer of signal transduction.
Role of Her2 in healthy tissue
In healthy tissue, Her2 signaling regulates cell differentiation, 
survival, and repair mechanisms (Casalini et al 2004). Cardiac 
myocytes for instance, are dependent on Her2 activation in 
their response to cellular stress. In this case, downstream sig-
naling induces repair mechanisms. Blocking this repair path-
way in connection with anthracycline exposure is often held 
responsible for the well known cardiotoxicity of trastuzumab 
(Fukazawa et al 2003). Another possible cause of cardiac 
toxicity is the interaction of Her2 with RLIP76 (RALBP1), 
a multifunctional transporter involved in signaling and trans-
membrane movement of solute allocrites which includes 
several antineoplastic agents. In fact, RALBP1 appears to be 
the dominant anthracycline transporter in the heart (Yadav 
et al 2004). In embryogenesis, Her2 was found to assist in 
proper cell differentiation (Casalini et al 2004). In cases where 
the Her2 pathway is deregulated, carcinogenesis results.
Assessment of Her2 status
Deﬁ  nition of Her2-positivity results from increased receptor 
expression or gene ampliﬁ  cation. As Her2 overexpression 
and ampliﬁ  cation have important consequences both for 
prognosis and treatment, accurate determination is necessary. 
Currently, two different methods are being used worldwide, 
immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH). IHC is a semiquantitative method 
that identiﬁ  es Her2 expression on the cell surface, with a 
grading system of 0 to 3+ positive. Tumors are classed as 
Her2-positive if they have a staining intensity of 3+ (when Biologics: Targets & Therapy 2007:1(1) 21
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receptor levels approach 2 million); if a score of ++ (recep-
tor levels of approximately 500,000) is gained, the tumors 
should be reanalyzed using FISH; tumors with Her2 gene 
ampliﬁ  cation again are deemed Her2 positive. This testing 
algorithm is accepted by many authors as a viable, cost 
effective approach (Ellis et al 2000; Larsimont et al 2002). 
More recently, alternative options for Her2 testing have 
been described: chromogenic in situ hybridization (CISH) 
(Denoux et al 2003), and real time polymerase chain reac-
tion (RT-PCR) (Gjierdrum et al 2004). The exact assessment 
of Her2 status is of utter importance, as only patients with 
strong overexpression or gene ampliﬁ  cation may expect to 
derive beneﬁ  t from trastuzumab treatment.
Trastuzumab
For nearly 10 years, the use of trastuzumab has been ﬁ  rmly 
established in Her2-positive breast cancer. The drug has 
dramatically changed response rate and progression-free 
survival in metastatic disease. More importantly even, 
disease-free survival and overall survival in the adjuvant 
setting were improved.
Mechanism of action
Trastuzumab is a recombinant, humanized monoclonal anti-
body (rhMab4D5), targeting the extracellular domain of Her2 
(human EGFR related), also known as erbB2 or neu (Hynes 
and Stern 1994; Nahta et al 2006). It is currently the only 
Her2-targeted therapy approved by the FDA for metastatic 
breast cancer. The drug inhibits cleavage of the extra cellular 
domain (Molina et al 2001) and, via antibody-dependent 
cellular cytotoxicity (ADCC) and complement dependent 
cytotoxicity (CDC), leads to cell degradation (Cooley et 
al 1999; Gennari et al 2004; Clynes et al 2006). Natural 
killer (NK) cells are necessary for the ADCC response to 
trastuzumab. They express Fc gamma receptors which bind 
the Fc domain of the IgG1 antibody, thereby activating NK 
cells to destroy cells expressing Her2 by lyses. This was 
validated in a mouse model where a signiﬁ  cant reduction 
in trastuzumab efﬁ  cacy was observed in mice lacking the 
Fc receptor (Clynes et al 2006). Other important mechanisms 
of action comprise the internalization and degradation of 
Her2 receptor protein (Cuello et al 2001), decrease of cyclin 
dependent kinase 2 (CDK2) activity via p27 induction (Lane 
et al 2001), blockade of downstream Her2 signaling pathways 
(Yakes et al 2002), and inhibition of DNA repair (Nahta et al 
2006). The latter point is deemed to be especially important 
for the described synergistic interaction with cisplatin and 
irradiation (Pietras et al 1994, 1998, 1999). It is unclear, how-
ever, whether trastuzumab actually causes downregulation of 
Her2, as some studies have demonstrated that receptor levels 
remain basically unchanged on trastuzumab therapy (Lane 
et al 2001; Yakes et al 2002; Nahta et al 2002). A summary 
of potential mechanisms of action is provided in Table 1.
Mechanisms of resistance
In general, while considerable knowledge has been gained 
during recent years, different questions remain unanswered 
still. This mainly concerns the mechanisms of resistance to 
trastuzumab. Obviously, de novo resistance exists, as only 
approximately one third of patients on trastuzumab mono-
therapy have objective response, thereby rendering response 
rate less than satisfactory (Vogel et al 2002). Also, second-
ary resistance eventually develops, as the majority of initial 
responders demonstrate disease progression within 1 year of 
treatment initiation (Nahta et al 2006).
Possible mechanisms of resistance comprise activation of 
downstream signaling pathways via insulin-like growth factor-1 
(IGF-1) (Lu et al 2001), and phosphatase and tensin homologue 
Table 1 Mechanism of action, trastuzumab
Molecular mechanism  Evidence
Inhibition of Her2 extracellular domain cleavage  Inhibition of proteolytic cleavage of the extracellular domain in vitro (Molina et al 2001)
Immune effects  Trastuzumab activated ADCC in many breast cancer cell lines. Level of ADCC correlated with
    response to therapy in vivo (Cooley et al 1999; Gennari et al 2004; Clynes et al 2006)
Her2 receptor   Downregulation of Her2 protein in breast cancer cell lines (Cuello et al 2001)
  Internalization and degradetion 
Decresed CDK2 (cyclin dependent kinase 2)  In vitro treatment of breast cancer cell
  activity     lines increased p27, resulting in reduced CDK2 activity (Lane et al 2001)
Blockade of Her2 signaling  Blockade of the PI3-Kinase/Akt pathway, as evidenced by decrease of phosphorylated Akt levels
    (Yakes et al 2002)
Inhibition of DNA repair  Inhibition of DNA repair and blockade of unscheduled DNA synthesis after damage by cisplatin
    and radiation (Pietras et al 1994, 1998, 1999)
Reduced angiogenesis  Reduced VEGF levels on trastuzuman treatment in breast cancer xenograft models 
    (Yen et al 2002)Biologics: Targets & Therapy 2007:1(1) 22
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loss (PTEN) (Nagata et al 2004), which enables activation of 
downstream signaling independent of receptor activity. Further, 
apparently decreased interaction between trastuzumab and its 
target receptor might occur, which in some cases is due to ste-
ric hindrance of Her2 by cell surface proteins such as mucin-4 
(MUC4) (Nahta et al 2006). In other cases, resistance is con-
veyed by a truncated Her2 receptor without extracellular domain 
due to alternative splicing. This speciﬁ  c receptor is commonly 
known as truncated Her2. From that, a constitutively activated 
Her2 protein results, without possibility of trastuzumab binding 
(Esparis-Ogando et al 1999). Also, constitutive Akt signaling 
was shown to inhibit the cell-cycle arrest and apoptotic effect of 
trastuzumab (Clark et al 2002). As outlined above, trastuzumab 
activity is in part due to p27 induction. Consequently, the down-
regulation of p27 was reported to be associated with trastuzumab 
resistance in breast cancer cell lines (Nahta et al 2004). Possible 
mechanisms of resistance are summarized in Table 2.
Advanced breast cancer
Early trials
In parallel to two small phase II that established the activity 
of trastuzumab in humans (Baselga et al 1996; Pegram et al 
1998), a large, randomized, single-agent study was initiated in 
April 1995. Response rate was found to be 15%, and median 
overall survival was 13 months. In the Her2 3+ subgroup, a 
considerably higher activity was observed, with an overall 
response rate of 18% and median survival of 16.4 months. 
Those results suggested that this group might derive the great-
est beneﬁ  t from trastuzumab (Cobleigh et al 1999).
Trastuzumab, taxanes, and anthracyclines
Two randomized, combination trials of trastuzumab and 
chemotherapy led the path to establishing the antibody in the 
treatment of Her2-positive metastatic breast cancer: H0648g 
and M77001.
A total of 469 patients without prior therapy for meta-
static breast cancer were included in H0648g. Patients who 
were not eligible for anthracycline treatment or who already
were exposed to an anthracycline in the adjuvant setting, were 
randomized to receive paclitaxel or paclitaxel plus trastu-
zumab. The reminders were randomized to doxorubicin plus 
cyclophosphamide with or without trastuzumab. Response 
rate, progression-free survival, and overall survival were su-
perior in the combination group. A subset analysis revealed 
that patients with IHC 3+ positive disease gained the largest 
beneﬁ  t, compared with the total population (IHC 2+ and 3+ 
positive). Further, it was observed that in the trastuzumab plus 
anthracycline group, 28% of patients experienced a cardiac 
event, compared with 13% in the population treated with 
paclitaxel plus trastuzumab (Slamon et al 2001). Due to these 
ﬁ  ndings, the combination of anthracyclines and trastuzumab is 
currently not deemed standard of care, although cardiotoxic-
ity might be less pronounced when liposomale doxorubicin 
is applied. This was evaluated in the M77035 trial. Within 
this trial, the triple combination of trastuzumab, paclitaxel, 
and TLC D-99 (Myocet®) was generally well tolerated. By 
formulating doxorubicin within a liposome, cardiac toxicity 
was minimized compared with conventional anthracyclines, 
while activity was maintained (Baselga et al 2004).
M77001 included patients with Her2-positive disease and 
randomized them to either receive docetaxel monotherapy or 
a combination of docetaxel plus weekly trastuzumab. Again, 
response rates, time to progression, and overall survival 
were superior in the trastuzumab containing arm, without 
adding signiﬁ  cantly to the toxicity proﬁ  le of docetaxel alone 
(Marty et al 2005).
Owing to these results, the combination of trastuzumab 
plus taxanes is deemed the golden standard in the ﬁ  rst line 
treatment of Her2-positive metastatic breast cancer (Jakisch 
et al 2006). Yet, as taxanes are increasingly incorporated 
into the adjuvant setting, interest in further combination 
strategies evolved. Based on a preclinical trial conducted by 
Pegram et al cyctotoxic agents and trastuzumab were classed 
either as synergistic, agonistic, or antagonistic (Pegram et al 
1999). Data were gained both from cell culture and a tumor 
xenograft model. Based on the results of this trial, special 
emphasis was put on combinations with vinorelbine and plati-
num compounds (as for these agents a synergistic interaction 
was assumed), while due to a suggested antagonistic effect of 
trastuzumab with 5-FU, the oral 5-FU prodrug capecitabine 
was of less interest until recently.
Table 2 Mechanism of resistance, trastuzumab
Proposed mechanism
Activation signaling pathways downstream insulin-like growth factor-1
  (IGF-1) (Lu et al 2001)
Loss of PTEN enables activation of downstream signaling independent of 
  receptor activity (Nagata et al 2004)
Decreased interaction of trastuzumab and Her2 due to steric hindrance 
  of Her2 by cell surface proteins such as mucin-4 (MUC4) (Nahta et al
 2006)
Truncated Her2 receptor without extracellular domain, resulting in a 
  constitutively activated Her2 protein, without the possibility of trastu-
  zumab binding (Esparis et al 1999)
Constitutive Akt signaling activates downstream signaling independent of 
  receptor activation (Clark et al 2002)
Downregulation of p27 is associated with trastuzumab resistance in 
  breast cancer cell lines (Nahta et al 2006)Biologics: Targets & Therapy 2007:1(1) 23
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Trastuzumab and vinorelbine
A number of phase II trials reported high activity and good 
tolerability of trastuzumab plus vinorelbine combinations in 
metastatic breast cancer. In these trials, different schedules 
of trastuzumab (weekly and every 3 weeks) and vinorelbine 
(both intravenous and oral vinorelbine) were used. In general, 
combination therapy was well tolerated, with reported response 
rates in the range of 50%–80% (Jahanzeb et al 2002; Burstein 
et al 2003a; Papaldo et al 2006). As expected, ﬁ  rst-line therapy 
yielded higher objective response rates and longer time to dis-
ease progression, possibly indicating that ﬁ  rst-line therapy with 
this combination may be more effective than later treatment 
(Jackisch et al 2006). A recently published phase II trial of 
oral vinorelbine plus trastuzumab suggested that intravenous 
vinorelbine could be substituted for by the oral formulation, 
without a decrease in efﬁ  cacy (Bartsch et al 2007a). Burstein 
et al addressed the important question whether the combination 
of trastuzumab with vinorelbine or a weekly administered tax-
ane would be the optimal ﬁ  rst-line regimen for Her2-positive 
metastatic breast cancer (Burstein et al 2006). The trial was 
closed due to slow accrual in December 2003, after having 
accrued only 85 of a planned 250 patients. While therefore the 
results must be interpreted with caution, this trial suggested at 
least comparable clinical activity of the two combinations, with 
a trend towards superior time to progression in the vonorelbine 
group (8.5 months vs 6.0 months; p = 0.09).
Trastuzumab and platinum compounds
In one of the earliest cinical trials, Pegram and colleagues 
reported on 37 patients with metastatic breast cancer who 
had received extensive prior chemotherapy. The subjects 
were treated with a 250 mg loading dose of trastuzumab 
followed by weekly doses of 100 mg until desase progres-
sion, in combination with cisplatin. Nine patients (24%) had 
a partial response (Pegram et al 1998).
In the last decade, a number of trials have reported results 
of trastuzumab in combination with platinum compounds, 
either as single agent or in combination with taxanes. These 
trials reported response rates ranging from 48% (single 
agent cisplatin) to approximately 80% in trials using the 
combination of platinum salts and taxanes (for a review 
see Tokunaga et al 2006; Demonty et al 2007). A recently 
published study compared the triple combination of trastu-
zumab, paclitaxel and carboplatin with trastuzumab plus 
paclitaxel alone (Robert et al 2006). The addition of carbo-
platin improved both overall response rate (52% vs 36%; 
p = 0.03) and progression-free survival (13.8 months vs 7.6 
months; p = 0.005). A second trial (BCIRG 007), evaluating 
the efﬁ  cacy of docetaxel, carboplatin plus trastuzumab, how-
ever, brought different results. The authors concluded that the 
already effective docetaxel plus trastuzumab regimen does 
beneﬁ  t from the addition of carboplatin in women with Her2 
overexpressing metastatic breast cancer (Forbes et al 2006).
In general, bearing in mind the relative high toxicity of 
such regimens, the combination of platinum compounds and 
trastuzumab appears to be a reasonable treatment option in 
selected patients with metastatic breast cancer.
Combinations with other cytotoxic agents
Data for the combination of trastuzumab with gemcitabine 
are available from two phase II trials. In both of these stud-
ies, patients with prior exposure to at least an anthracycline 
and/or taxane were included. Response rates were 36% and 
38% respectively, and treatment in general was well toler-
ated. Notably, in a total of 89 patients included, no case of 
congestive heart failure was observed (Christodoulou et al 
2003; O´Shaughnessy et al 2004).
As outlined above, in vitro studies suggested an antago-
nistic effect of combining 5-FU and trastuzumab; in effect, 
the combination was considered less effective than either 
drug alone (Pegram et al 1999). However, further trials 
with human breast cancer models showed at least an addi-
tive effect of this combination (Fujimoto-Ouchi et al 2002). 
This conclusion was strengthened by available clinical data. 
A small trial incorporated heavily pretreated patients with 
Her2-positive breast cancer. At the ASCO 2005 meeting an 
encouraging response rate of 60% was reported (Schaller 
et al 2005). These results were mirrored by data presented 
by Xu et al who conducted a phase II trial of capecitabine 
and trastuzumab in the ﬁ  rst line setting (Xu et al 2006). A 
recent single-center trial of trastuzumab plus capecitabine 
beyond progression reported a time to progression (TTP) 
of 8 months and a clinical beneﬁ  t rate of 70% (Bartsch 
et al 2007b). Still, while there is growing evidence that the 
combination of capecitabine with trastuzumab is active, this 
regimen remains largely experimental.
In the MO16419 (CHAT) trial, patients were randomized 
to receive docetaxel plus trastuzumab, either with or without 
capecitabine, as ﬁ  rst-line therapy for Her2-positive metastatic 
breast cancer. Overall response rate, which was deﬁ  ned as 
primary endpoint, was high in both treatment arms, with no 
signiﬁ  cant difference (71% in the triple combination arm, 
compared with 73% in patients on docetaxel plus trastu-
zumab). In terms of TTP, there was a signiﬁ  cant beneﬁ  t for 
the docetaxel, trastuzumab plus capecitabine (18.2 months 
vs 13.8 months, p = 0.045) combination. Differences in pro-Biologics: Targets & Therapy 2007:1(1) 24
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gression-free survival and overall survival, however, did not 
reach statistical signiﬁ  cance. It must therefore be assumed 
that the addition of capecitabine does not add to the efﬁ  cacy 
of docetaxel plus trastuzumab.
Independently of cytotoxic combination partners, current 
results clearly recommend early use of trastuzumab in the 
metastatic setting (ie, from ﬁ  rst line) (Slamon et al 2001; 
Harris and Smith 2002).
Trastuzumab and endocrine therapy
New data are available concerning the combination of trastu-
zumab and endocrine substances in the palliative setting 
(Kaufmann et al 2006). In the Tandem trial, combination 
of trastuzumab and anastrozole was superior to anastrozole 
alone in Her2- and ER- and/or PgR-positive breast cancer 
in terms of response rate and progression-free survival. A 
non-signiﬁ  cant trend towards prolonged overall survival was 
observed. As outlined above, the assumed biological basis 
for this study is a crosstalk between the estrogen receptor and 
growth factor pathways, making a ligandless activation of the 
ER via Her2 possible, thereby causing endocrine resistance 
(Schiff et al 2004).
Scheduling trastuzumab
In the pivotal trials and most of the following studies evaluat-
ing the role of trastuzumab either alone or in combination with 
chemotherapy, the standard weekly schedule of administrating 
the antibody was used. Based on newer data suggesting a longer 
half-life of trastuzumab than originally believed, Leyland-Jones 
et al initiated a trial evaluating trastuzumab and paclitaxel with 
a more convenient regimen with a 3-weekly administration of 
both drugs. A pharmacokinetics sub-protocol revealed no major 
differences between the three-weekly schedule and data from 
trials utilizing the weekly regimen (Leyland-Jones et al 2003). 
The same results were reported by a European group evaluating 
a 3-weekly schedule (Baselga et al 2005). While unfortunately 
no formal, direct, randomized, comparison of these two regimens 
was performed, in the light of available data it appears reasonable 
to offer patients the possibility of the 3-weekly regimen.
Treatment beyond progression
A major unresolved question about trastuzumab treatment 
in advanced breast cancer concerns treatment beyond 
progression. After progressing on a combination of trastu-
zumab and chemotherapy, should trastuzumab be discon-
tinued, or only the cytotoxic partner switched to another 
substance, while antibody treatment continues? As of today, 
no results from randomized clinical trials are available. For 
daily clinical practice, however, some preclinical and clini-
cal evidence supports ongoing trastuzumab therapy beyond 
disease progression.
In a Her2-positive human xenograft model, a decrease 
of trastuzumab levels caused tumor regrowth (Pietras et al 
1998). This might implicate a rebound effect after cessation 
of antibody therapy. Recently presented preclinical data 
showed the following results: Combination of trastuzumab 
with a taxane after failure of trastuzumab monotherapy was 
more effective than taxanes alone in this setting (Fujimoto-
Ouchi et al 2005). Clinical data are also available: In an 
extension study of the pivotal phase III trial, patients were 
given the opportunity to continue trastuzumab when on 
disease progression. Continuation of antibody therapy 
was safe and well tolerated; response rate was 11%, 
and response duration 6.7 months (Tripathy et al 2004). 
Other different groups also reported encouraging results 
(Fountzilas et al 2003; Bartsch et al 2006a). In one study, 
response rates and time to progression were maintained 
from ﬁ  rst to beyond second line treatment. Response rates 
were 42.6% in ﬁ  rst line trastuzumab therapy, 25.9% in 
second line, and 30% in beyond second line respectively. 
Median time to progression was 6 months in all treatment 
lines (Bartsch et al 2006a).
Early breast cancer
As outlined, up to 25% of women with early stage breast 
cancer have Her2-positive disease, which is well known to 
correlate with aggressive disease and a higher likelihood of 
recurrence after adjuvant therapy (Slamon et al 1989; Boss 
et al 2003). Due to the beneﬁ  ts of trastuzumab in the palliative 
setting, a number of adjuvant trials were initiated, to evaluate 
the possible role of the antibody in the prevention of cancer 
recurrence in this high risk population.
More than 13,000 women were included in a total of 5 
prospective adjuvant phase III trials that have ultimately lead 
to the deﬁ  nition of trastuzumab as golden standard in the 
adjuvant therapy of Her2-positive early breast cancer. Impor-
tantly, chemotherapy regimens and the timing of trastuzumab 
administration varied among the different studies. Therefore a 
number of unanswered questions concerning the optimal way 
to administer trastuzumab adjuvant remain. The designs of the 
adjuvant breast cancer trials are summarized in Figure 1.
HERA
This international, non-US, adjuvant multicenter trial ran-
domized patients after standard adjuvant therapy (minimal 
of 4 cycles of adjuvant/neoadjuvant chemotherapy with or Biologics: Targets & Therapy 2007:1(1) 25
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without radiotherapy) to 3 arms: a control arm, 1 year of 
trastuzumab, and 2 years of therapy. Disease-free survival 
was deﬁ  ned as primary endpoint. Initial data have been 
published in 2005. At 1 year of median follow up, a relative 
risk reduction of recurrence of 46% was observed in the treat-
ment group as compared with the observation group (hazard 
ratio [HR], 0.54; 95% conﬁ  dence interval [CI], 0.43–0.67; 
p < 0.0001). Further, a trend towards a prolonged overall 
survival was seen in the treatment group (Piccart-Gebhart 
et al 2005). This trend reached statistical signiﬁ  cance at the 
second planned interim analysis at a median follow up of 24 
months (HR, 0.64; 95% CI, 0.54–0.76; p = 0.005) (Smith 
et al 2006). Differing from the US trials NSABP-B31 and 
NCCTG N9831, a large number of node negative patients 
were included (approximately 32% in each arm).
Combined analysis of NSABP B-31 and NCCTG 
N9831
NSABP B-31 is a 2-arm, randomized phase III trial of 4 
cycles of doxorubicin and cyclophosphamide (AC) followed 
by 4 cycles of paclitaxel every 3 weeks (or 12 cycles of 
paclitaxel weekly) with or without trastuzumab. Treatment 
was initiated after completion of AC therapy. In contrast, 
NCCTG N9831 had a 3-arm design. Two arms were identi-
cal to the corresponding arms of B-31, a third arm initiated 
trastuzumab after the end of chemotherapy (ie, similar the 
HERA trial). Treatment also consisted of the US standard 
AC × 4 followed by 12 cycles of weekly paclitaxel. Therefore, 
after approval by the FDA was gained, a combined analysis 
of the two control arms and concurrent arms of those trials 
was possible. After 2 years of median follow up, patients 
treated with trastuzumab had a signiﬁ  cantly longer disease-
free survival as compared with the control group (HR, 0.48; 
95% CI, 0.39–0.59; p < 0.001). Also, a signiﬁ  cant beneﬁ  t in 
terms of overall survival was observed (HR, 0.67; 95% CI, 
0.48–0.93; p = 0.015) (Romond et al 2005).
BCIRG 006
A third, international trial, was initiated by the BCIRG. This 
3-arm study, conducted at centers in the US, Europe, South 
Africa, Asia, and Venezuela, had a very interesting design: 
a standard arm of AC × 4 followed by 4 cycles of docetaxel 
every 3 weeks was compared with the same regimen plus 
trastuzumab (initiated after AC) and a third (anthracycline-
free) arm consisting of carboplatin, docetaxel, and trastu-
zumab (TCH). The special value of this trial, therefore, is 
the evaluation of an anthracycline-free regimen. In the light 
of well known cardiac safety concerns, this might be an 
effective regime in patients with known pre-existing cardiac 
conditions. Initial results were presented at the 28th San 
Antonio breast cancer symposium (SABCS) in 2005. Both 
trastuzumab containing treatment arms had a signiﬁ  cantly 
improved disease free survival (which was deﬁ  ned as primary 
endpoint) as compared to the control arm. Still, there seemed 
to be a special beneﬁ  t for the anthracycline-containing 
arm, with a 51% lower risk of recurrence compared with 
a 39% risk reduction in the TCH arm (Table 3). Due to 
the fact that up to one third of tumors are co-ampliﬁ  ed for 
Her2 and topoisomerase IIα, it was assumed that this dif-
ference may become statistically signiﬁ  cant over time, and 
Figure 1 Trials evaluating the role of trastuzumab in early stage breast cancer.
Abbreviations: A, doxorubicin; C, cyclophosphamide; D, docetaxel; E, epidoxorubicin; F, 5-FU; P, paclitaxel; q3w, every 3 weeks; qw, weekly; RT, radiotherapy.
HERA (global, ex-USA) Observation
n = 5,090 Any C T +/−RT Trastuzumab q3w 1 year
Trastuzumab q3w 2 years
NSABP B-31 (USA) ÁC x 4 P q3w x 4 or P qw x12
n = 2,030 AC x 4 P q3w x 4 or P qw x 12 + Trastuzumab qw 1 year
NCCTG N9832 (USA) AC x 4 P qw x 12
n = 3,505 AC x 4 P qw x 12 Trastuzumab qw 1 year
AC x 4  P qw x12 + Trastuzumab qw 1 year
BCIRG 006 (global) AC x 4 D q3w x 4
n = 3,222 AC x 4 D q3w x 4 + Trastuzumab qw x12
D + Carboplatin q3w x 6 + Trastuzumab qw x 18
FinHER (Finland) D q3w x 3 or Vinorelbine qw x 8  FEC q3w x 3 
n = 232  D q3w x 3 or Vinorelbine qw x 8 + Trastuzumab qw x 9  FEC q3w x 3
(Her2 positive group)
Trastuzumab q3w x 13
Trastuzumab q3w x 11Biologics: Targets & Therapy 2007:1(1) 26
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the anthracycline plus trastuzumab arm would eventually 
prove to be the superior regimen (Slamon et al 2005). In 
2006, however, updated information became available. The 
trend observed before then had all but vanished. It must 
therefore be assumed that targeting a single, ampliﬁ  ed gene 
of the Her2 amplicon is sufﬁ  cient, and double targeting by 
trastuzumab plus an anthracycline is of no additional value 
(Slamon et al 2006). While these data are interesting, ﬁ  nal 
results and possibly further studies will have to be awaited 
before anthracycline-free regimens could be deemed standard 
in Her2 overexpressing breast cancer.
FinHER
The smallest of the ﬁ  ve adjuvant trials included only 232 
Her2-positive patients. The design was radically differ-
ent from the others: before having 3 cycles of CEF every 
3 weeks, patients either received 3 cycles of docetaxel 
every 3 weeks or 8 cycles of weekly vinorelbine. Further, 
Her2-positive patients were randomized either to a group of 
9 cycles of weekly trastuzumab, or control (Figure 1). Again, 
recurrence-free survival was deﬁ  ned as primary endpoint. 
While no difference in overall survival has been observed up 
to now, a signiﬁ  cant advantage in recurrence-free survival 
was found in patients receiving trastuzumab (HR, 0.42; 95% 
CI, 0.21–0.83; p = 0.01) (Joensuu et al 2006).
Due to the different designs of the adjuvant trials, a num-
ber of questions concerning the optimal use of trastuzumab 
in the adjuvant setting remain unanswered. For example, it 
is not know whether the optimal use of chemotherapy and 
trastuzumab is sequential or concurrent. Also, in the light of 
BCIRG 006 data, it must be asked which chemotherapy plus 
trastuzumab combination is the most effective and safe.
The question concerning the optimal duration of trastu-
zumab therapy is also still open, although it was indirectly 
approached in a study presented by Sledge et al at the SABCS 
2006 meeting. E2198 was a pilot trial examining the cardiac 
effects of paclitaxel plus trastuzumab prior to doxorubicin 
plus cyclophosphamide (AC) in Her2-positive patients. 
Patients received paclitaxel plus weekly trastuzumab for 
10 weeks followed by 4 cycles of AC. After completion of 
cheomotherapy, one arm received trastuzumab for a further 
52 weeks. Disease-free survival and overall survival showed 
no difference between the two groups. The authors concluded 
that although the trial was not designed or powered to test the 
question of trastuzumab duration, a signiﬁ  cant advantage for 
prolonged trastuzumab administration was not observed.
Therefore, although trastuzumab is now well established 
in the adjuvant therapy of Her2-positive breast cancer, further 
trials addressing the mentioned questions are awaited.
Role of trastuzumab in the neoadjuvant 
setting
Neoadjuvant chemotherapy (systemic chemotherapy before 
surgery) for breast cancer is standard of care in patients 
with locally advanced disease. While there is little doubt 
concerning the efﬁ  cacy of trastuzumab in the adjuvant set-
ting, the exact role of the antibody in the preoperative setting 
awaits further clariﬁ  cation. A number of phase II data, with 
pathologic complete remission (pCR) rates ranging from 
18% to 39%, are currently available, and deﬁ  nitely support 
evaluation in larger trials (Wenzel et al 2002; Burstein et al 
2003b; Jahanzeb et al 2005; Hurley et al 2006). Trials were 
utilizing highly different substances and regimens, and there 
is limited evidence from large phase III studies.
In the phase III trial conducted by Buzdar et al 42 patients 
were treated with 4 cylces of paclitaxel followed by another 4 
cycles of 5-FU, epidoxorubicin and cyclophosphamide (FEC) 
with or without weekly trastuzumab for 24 weeks. The trial was 
terminated prematurely after the ﬁ  rst 34 patients completed 
therapy, because a signiﬁ  cant difference in terms of pCR rate 
favoring the trastuzumab arm was observed (66.7% vs 25%; 
p = 0.02) (Buzdar et al 2005). Interestingly, a study conducted 
by the Austrian breast and colorectal study group (ABCSG) 
showed a signiﬁ  cantly higher pCR rate after 6 cycles of epi-
doxorubicin and docetaxel (ED) in patients with Her2-positive 
tumors in a multivariate analysis as compared with the Her2 
negative subgroup. This possibly indicates the assumed higher 
responsiveness of Her2-positive tumors to anthracyclines ex-
posure due to coampliﬁ  cation of topoisomerase IIα and Her2 
in one third of cases (Steger et al 1999; Slamon et al 2006; 
Steger et al 2007). Therefore, while results of preoperative tar-
geting of Her2 and its amplicon are deﬁ  nitely encouraging, the 
Table 3 Results BCIRG 006
BCIRG 006
  Disease-free survival  Overall survival
AC→TH vs AC→T  HR, 0.49; 95% CI, 0.37–0.65; p < 0.0001  HR, 0.59; 95% CI, 0.42–0.85; p = 0.004
TCH vs AC→TH  HR, 0.61; 95% CI, 0.47–0.83; p = 0.0003  HR, 0.66; 95% CI, 0.47–0.93; p = 0.017
Abbrevations: A, doxorubicin; C, cyclophosphamide; T, docetaxel; H, trastuzumab; TCH, docetaxel, carboplatin, trastuzumab.Biologics: Targets & Therapy 2007:1(1) 27
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neoadjuvant approach with trastuzumab still remains largely 
experimental. To further evaluate this question, ABSCG initi-
ated another randomized neoadjuvant protocol (ABSCG-24), 
incorporating preoperative chemotherapy with or without 
trastuzumab (ClinicalTrials.gov2007). Another important 
trial that will help clarifying the role of trastuzumab in the 
neoadjuvant setting will be conducted by the American college 
of surgeons oncology group (ACOSOG). In the ACOSOG 
Z1041 study, patients will be randomized to receive either 
paclitaxel and trastuzumab weekly for 12 weeks followed by 
4 cycles of FEC with weekly trastuzumab before surgery, or 
4 cycles of FEC followed by 12 cycles of weekly paclitaxel 
and trastuzumab (www.acosoc.org).
Trastuzumab retreatment after recurrence following 
adjuvant trastuzumab With the establishment of antibody 
therapy in early stage Her2-positive breast cancer, recurrence 
rate was reduced by approximately 50%. Still, some patients 
will experience disease recurrence on, or after antibody 
therapy. Therefore, there is an urgent need to answer the 
question, whether trastuzumab should be re-induced in 
these individuals. Data from the RHEA (retreatment after 
herceptin adjuvant) phase II trial, which is currently ongoing, 
will hopefully provide information concerning this problem 
(ClinicalTrials.gov2007).
Drawbacks and side-effects
A problem arises from the fact that monoclonal antibodies 
cannot pass an intact blood–brain barrier. With trastuzumab, 
an increased incidence of breast cancer brain metastases 
was observed (Bendell et al 2003; Clayton et al 2004; 
Shmueli et al 2004). This is explained by two interacting 
mechanisms. First, as outlined above, large molecules 
cannot pass into the brain and the cerebral liquor, and 
thus cannot prevent the development of cerebral disease. 
Secondly, survival in this high risk population is prolonged 
due to the antibody. As result, patients who might have 
died from systemic disease progression, survive to de-
velop cerebral disease. Although there is some evidence 
concerning possible activity of systemic treatment in brain 
metastases due to an impairment of the blood-brain-bar-
rier around metastatic sites and due to irradiation (Rosner 
et al 1986; Boogerd et al 1992; Bartsch et al 2006b), no 
truly and long-term active treatment of this debilitating 
complication exists, and brain metastases remain a major 
problem. Therefore, other solutions must be sought. A 
possible answer lies in the use of lapatinib in this situation. 
Due to their molecular weight, tyrosine kinase inhibitors 
are in theory able to pass the blood brain barrier. This was 
strengthened by data presented at the ASCO 2006 meeting, 
where a stabilization of cerebral lesions in patients treated 
with lapatinib was reported (Lin et al 2006). The question 
was also approached in a trial comparing the combination of 
capecitabine and lapatinib versus capecitabine monotherapy 
after trastuzumab failure (Geyer et al 2006). Fewer patients 
in the combination group developed cerebral disease.
While trastuzumab in general is well tolerated, the best 
known side-effect of course is the increased incidence of 
congestive heart failure (CHF). This was ﬁ  rst observed in the 
pivotal trial in the metastatic setting, with notably the high-
est occurrence rates in patients treated with a combination of 
doxorubicin plus trastuzumab (Slamon et al 2001). Therefore 
this combination was avoided in following studies. In the 
Figure 2 Mechanism of action, trastuzumab, and lapatinib.
TK TK TK
X                     X X lapatinib
membrane
X   X X trastuzumab Different blockade of downstream signaling of
ErbB family members by trastuzumab and lapatinib
Trastuzumab, a humanized monoclobal antibody,
targets the extracellulardomain of Her2, and, via
different mechanisms, causes cell degradation
(Table 1)
Lapatinib blocks tyrosine kinase activity of
EGFR and Her2, thereby blocking downstream
signaling of EGFR and Her2
homo- and heterodimers
1 + 1 2 + 2 1 + 2
TK = Tyrosine Kinase
     Domain
downstream signaling pathwaysBiologics: Targets & Therapy 2007:1(1) 28
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adjuvant setting, approximately 5% of patients are expected 
to develop some form of cardiac function impairment, and 
1% may develop symptomatic CHF (Perez and Rodeheffer 
2004; Piccart-Gebhart et al 2005; Romond et al 2005). In 
most cases, the systolic dysfunction appears to be reversible 
(Guarneri et al 2006); still, close monitoring of patients on 
trastuzumab treatment is mandatory. Especially at risk for 
developing a drop in left ventricular ejection fraction (LVEF) 
are patients of old age and with known hypertension; further 
risk factors may include pre-existing diabetes, coronary
artery disease, and valvular dysfunction (Romond et al 2005; 
Guarneri et al 2006). An algorithm for controlling the cardiac 
function of patients while on trastuzumab was proposed by 
Keefe (2002). The author suggests close surveillance with echo-
cardiography or MUGA scan every 4 weeks if a drop in LVEF 
occurs. In asymptomatic cases, antibody treatment should be 
held when a drop of >20 points to <40% is observed, or when 
LVEF falls below 30%. In symptomatic CHF, treatment should 
be stopped in case LVEF drops by more than 30 points.
Other possible side-effects consist mainly of anaphylactic 
reactions; the HERA trial reported a minimally increased 
risk of infections (22 patients [1.3%] vs 7 patients [0.4%] 
in the control group) (Piccart-Gebhart et al 2005), and the 
combined analysis of NSABP B-31 and NCCTG N9831 
trials reported rare cases of interstitial pneumonitis that in 
some cases appeared to be related to trastuzumab therapy (4 
cases in B-31 and 5 in N9831). In BCIRG 006, there were 
no signiﬁ  cant differences in grade 3 or 4 hematologic or 
nonhematologic adverse events among the 3 treatment arms 
(Slamon et al 2005). Also, in the FinHER trial, no differences 
in adverse events were observed in the respective trastuzumab 
and non-trastuzumab groups (Joensuu et al 2006).
It may therefore be stated that while the cardiac toxicity 
is evident, trastuzumab in general is well tolerated, and the 
beneﬁ  ts by far outweigh the potential risks and side-effects. 
Still, close cardiac monitoring is required.
An outlook: combinations 
of trastuzumab and other targeted 
agents 
Lapatinib is an orally available tyrosinkinase kinase inhibitor 
blocking the tyrosine kinase domains of EGFR and Her2 
(Figure 2). There is little doubt that this compound is of value 
in Her2-positive breast cancer, especially in the metastatic 
setting. Lapatinib is active in combination with capecitabine 
after trastuzumab exposure (Geyer et al 2006), and might 
be active also in cerebral lesions (Lin et al 2006). A phase 
I study presented at the ASCO 2005 meeting reported 
an impressive, while short lived (2–8 months), response 
rate with a trastuzumab lapatinib combination (Storniolo 
et al 2005). The EGF 104900 trial is currently further inves-
tigating this combination. After exposure to capecitabine, 
a taxane, an anthracycline, and trastuzumab, patients are 
randomized to receive either lapatinib 1500 mg or a combina-
tion of lapatinib 1000 mg in combination with weekly trastu-
zumab (ClinicalTrials.gov2007). Further, a number of trials 
evaluating the combination of lapatinib, trastuzumab, and 
chemotherapy (docetaxel, paclitaxel, carboplatin, doxorubi-
cin) are currently recruiting (www.ClinicalTrials.gov2007). 
The substance will be also evaluated in the adjuvant setting 
in the ALTTO trial (ClinicalTrials.gov2007). In this 4-arm 
trial following standard chemotherapy, an adjuvant 1 year 
trastuzumab arm will be compared with a 1 year lapatinib 
arm and 2 combination arms, one in which the two drugs are 
administered sequentially (12 weeks of lapatinib followed by 
6 months of trastuzumab) and 1 combination arm in which 
the two drugs are administered simultaneously for 1 year.
Another approach is the combination of 2 monoclonal 
antibodies targeting different receptors of the Her family. 
At our center, a trial combining trastuzumab and cetuximab 
is being conducted in patients with metastatic breast cancer. 
Cetuximab is a chimeric monoclonal antibody, targeting 
the extracellular domain of EGFR (Lenz 2006). Although 
the drug is well established in metastatic colorectal can-
cer, and also in head and neck tumors (Cunningham et al 
2004; Bonner et al 2006), it has not yet found its way into 
breast cancer therapy. As described, a powerful interaction 
between Her2 and EGFR exists. It is hypothesized that by 
blocking both growth factor receptors, the resulting down-
stream signaling can be blocked in a more efﬁ  cient manner; 
further an increased immune response is anticipated. This 
combination might also be of value in Her2 1+ or 2+, FISH 
negative disease.
Bevacizumab is a humanized monoclonal antibody 
targeting vascular endothelial growth factor (VEGF), 
which is of great importance for tumor vasculature and 
therefore tumor growth. This antibody might ﬁ  nd a role 
in Her2-positive disease. The rationale is that through 
increased signaling via the ras/raf/MAPKinase signaling 
pathway, HIF-1α levels increase (Laughner et al 2001), 
and, consecutively, so does VEGF expression (Yen et al 
2000; Izumi et al 2002). This mechanism may be blocked by 
trastuzumab by downregulating the MAPKinase pathway. 
Therefore, combining these two antibodies might target 
tumor vessel growth more effectively than either compound 
alone (Pegram et al 2002). A phase II trial recently Biologics: Targets & Therapy 2007:1(1) 29
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presented at the 2006 SABCS reported this combination to 
be clinically feasible and highly active in Her2 ampliﬁ  ed 
recurrent or metastatic breast cancer (Pegram et al 2006). 
Based on this rationale, a randomized multicenter study is 
currently underway, evaluating docetaxel plus trastuzumab 
with or without bevacizumab in the ﬁ  rst line metastatic 
setting (ClinicalTrials.gov2007).
Conclusion
Molecular targeted treatment is of great promise in cancer 
therapy. Targeting Her2 with the monoclonal antibody trastu-
zumab has dramatically changed the prognosis of patients 
with Her2-positive breast cancer, both in advanced and early 
stage disease. While this drug therefore evolved as the gold 
standard, a number of questions remain unanswered.
In advanced breast cancer, among other uncertainties, 
there is no consensus regarding the optimal trastuzumab 
schedule (weekly vs every 3 weeks), the optimal chemo-
therapy combination partners, and treatment beyond progres-
sion. In early-stage disease, questions remain concerning 
anthracycline-free chemotherapy regimens, the time point of 
trastuzumab initiation, and treatment duration. Yet the largest 
challenge remaining is to identify mechanisms of resistance 
to trastuzumab, and possible ways to overcome these.
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